Description
Prodynov is a third-generation photosensitizer (PS).
It targets folate receptors that are overexpressed in cancer cells of the ovary, liver, and pancreas.
The proof-of-concept studies conducted to date have focused on peritoneal carcinomatosis.
When illuminated by a dedicated light-delivery device, this photosensitizer exhibits a three-part mechanism of action:
- Fluorescence-guided visualization of cancer cells to facilitate surgical removal
- Lysis of tumor cells that cannot be reached surgically
- Activation of the immune system
Additional key features:
- Water-soluble, with greater efficacy than 5-ALA
- “Pre-GMP” synthesis in three steps, with a detailed protocol for the optimized synthetic route
- Analytical method for identification, quantification, and purity assessment
- Method for Solubilization and Pre-formulation
- In vitro and in vivo ADME-Tox, DMT, PK, efficacy demonstrated in mice and pigs
IP: 1 Patent TRL: In vivo proof of concept (4/5) Partnership: Licensing